Contains Proteins Or Derivative Or Polysaccharides Or Derivative Patents (Class 424/499)
-
Publication number: 20130316004Abstract: Methods for increasing the stability of, or protecting, labile components such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium. Stability of the labile compound is increased either, by derivatization of the labile compound with chemicals, or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule, or by the use of sequestering agents. Encapsulation includes the encapsulation of dendrimers complexes of susceptible compounds within the microcapsule, thereby providing the controlled release of the susceptible compound that was protected. These methods may improve and extend storage conditions of compositions comprising the labile compounds, improve shipping and handling of compositions comprising the labile compounds, such as dry media formulations, at room temperature rather than at lower temperatures thereby decreasing shipping costs.Type: ApplicationFiled: February 7, 2012Publication date: November 28, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Richard Fike, Bruce Branchaud, Shawn Barrett
-
Patent number: 8591955Abstract: The present invention provides an orally rapidly-disintegrating tablet comprising at least two particles. Regarding medicaments with unpleasant taste, the present invention provides a tablet comprising such medicament having a suitable hardness so that the tablet can be handled without any difficulty in the period from the formulation of the tablet to the administration thereof (in particular, a tablet which can maintain the hardness thereof when it is stored under a humidified condition); a small size; no unpleasant taste; a pleasant feeling in a mouth after administration; and an excellent disintegration character in the oral cavity and an excellent dissolution character in the gastrointestinal tract.Type: GrantFiled: August 11, 2010Date of Patent: November 26, 2013Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventor: Keiichi Fujiwara
-
Publication number: 20130295170Abstract: Opiates, amphetamines, barbiturates and other drugs such as benzodiazepines are extensively abused or misused and are frequently the cause of death by overdosing. These drugs are also prone to oxidation and the final degradation products depend on the reactants and the reaction conditions. This invention describes the use of inactivating agents such as permanganates, peroxides, persulfates, bismuthates, periodates or other oxidants in a dosage form as an approach to minimize abuse and overdose. The product is designed such that the inactivating agent is released if there is an attempt to extract the drug from the formulation or in cases of overdose. Once released, the inactivating agent quickly degrades the drug and converts it into inactive compounds. Since the reactants (drug and inactivating agent) are incompatible in situations of normal drug usage, they are kept separated within the vehicle of the invention, but released for interaction in case of misuse.Type: ApplicationFiled: May 3, 2013Publication date: November 7, 2013Applicant: KYDES Pharmaceuticals LLCInventor: Stephen Dordunoo
-
Publication number: 20130295190Abstract: The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicant: New Jersey Institute of TechnologyInventors: Ecevit Bilgili, Rajesh Dave, Anagha Bhakay, Mohammad Azad
-
Patent number: 8574629Abstract: An injectable hydrogel includes a hydrogel matrix based on (a) single-phase-type cross-linked biopolymer(s), characterized in that previously cross-linked biopolymer hydrogel particles are co-cross-linked with the matrix. A method of and a process for production of the above-mentioned hydrogel are also disclosed.Type: GrantFiled: July 30, 2009Date of Patent: November 5, 2013Assignee: Anteis S.A.Inventor: Samuel Gavard Molliard
-
Patent number: 8568787Abstract: Provided is a method of producing hydroxyalkylcellulose microparticles, the method including generating a pulse shock wave, and supplying a hydroxyalkylcellulose aqueous solution to the pulse shock wave generation region, thereby crushing and drying the hydroxyalkylcellulose aqueous solution. According to the production method, hydroxyalkylcellulose microparticles having a volume-average particle size of at least 0.1 ?m but less than 15 ?m are obtained. By mixing the hydroxyalkylcellulose microparticles with a principal agent and subjecting the resulting mixture to a tablet compression, a solid preparation having excellent tensile strength and disintegration properties can be obtained.Type: GrantFiled: November 24, 2010Date of Patent: October 29, 2013Assignee: Nippon Soda Co., Ltd.Inventors: Hirofumi Takeuchi, Satoru Abe, Takeshi Shimotori, Gentaro Nemoto
-
Patent number: 8568786Abstract: A method of controlling a physical characteristic of polymeric nanocarrier-encapsulated protein particles includes altering or selecting a weight percentage of a hydrophobic polymer block in a total amphiphilic diblock copolymer of a primary emulsion of a double emulsion, freeze-thaw technique. The primary emulsion is formed using a freeze-thaw cycle of the amphiphilic diblock copolymer and a protein having a molecular weight of up to or equal to 300,000 Da. Selection of the hydrophobic polymer block percentage alters one or more characteristics of the resulting nanoparticles, such as shape. Thus, as one aspect, a method of producing filamentous polymeric nanocarrier-encapsulated protein (i.e.Type: GrantFiled: October 27, 2008Date of Patent: October 29, 2013Assignee: The Trustees of the Universtiy of PennsylvaniaInventors: Eric Simone, Vladimir R. Muzykantov, Thomas D. Dziubla
-
Publication number: 20130280336Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.Type: ApplicationFiled: February 27, 2013Publication date: October 24, 2013Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
-
Publication number: 20130280337Abstract: The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.Type: ApplicationFiled: February 27, 2013Publication date: October 24, 2013Inventors: Neil P. DESAI, Patrick SOON-SHIONG
-
Publication number: 20130273148Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Inventors: Charles RICHARDSON, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Publication number: 20130273171Abstract: A stable formulation of dexlansoprazole for treating a digestive disorder, and methods of manufacturing the same.Type: ApplicationFiled: November 18, 2010Publication date: October 17, 2013Applicant: HANDA PHARMACEUTICALS, LLCInventors: Zhiqun Shen, Yu Zhang, Enjun Fu, MIn Michael He, Fang-yu Liu
-
Publication number: 20130266661Abstract: The present invention relates to an amphiphilic cyclic phosphazene trimer which is biocompatible and a method for preparing the same. The present invention also relates to pharmaceutical formulations of hydrophobic drugs that are micelle-encapsulated by the amphiphilic cyclic phosphazene trimer and a method for preparing the same.Type: ApplicationFiled: December 16, 2011Publication date: October 10, 2013Applicant: CNPHARM CO., LTD.Inventors: Youn Soo Sohn, Yong Joo Jun
-
Publication number: 20130243873Abstract: Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.Type: ApplicationFiled: November 25, 2011Publication date: September 19, 2013Applicant: Sigmoid Pharma LimitedInventors: Vincenzo Aversa, Ivan Coulter, Mónica Torres Rosa, Bernard Francis McDonald
-
Patent number: 8529960Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529956Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: April 17, 2008Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Carnegie Mellon University, Allegheny-Singer Research InstituteInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529939Abstract: The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.Type: GrantFiled: December 8, 2004Date of Patent: September 10, 2013Assignee: Gel-Del Technologies, Inc.Inventors: David B. Masters, Eric P. Berg
-
Patent number: 8529959Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529958Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529961Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Publication number: 20130230580Abstract: Provided are therapeutics, uses and methods in which neuro-regenerative therapy using neuroprotective agents, or anti-neuropathic agents, to prevent loss or restore hematopoietic capacity and progenitor mobilization.Type: ApplicationFiled: September 14, 2011Publication date: September 5, 2013Inventors: Paul S. Frenette, Daniel Lucas-Alcaraz
-
Publication number: 20130230598Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: ApplicationFiled: February 20, 2013Publication date: September 5, 2013Applicant: LG LIFE SCIENCES, LTD., INC.Inventors: Myung-Jin KIM, Sun-Jin KIM, Oh-Ryong KWON
-
Patent number: 8524279Abstract: A method and apparatus are provided for atomizing a liquid under dispersal conditions suitable for spray drying at a commercial plant scale. In one embodiment, a liquid atomizer has a structural body adapted for connection with a spray dryer and a plurality of atomizing nozzles. Each of the atomizing nozzles includes a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas. In another embodiment, a process for producing a powder blend of at least two target substances in a single processing step is provided.Type: GrantFiled: October 31, 2002Date of Patent: September 3, 2013Assignee: Novartis AGInventors: Herman E. Snyder, Michael J. Vosberg, Christopher M. Varga
-
Patent number: 8524368Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.Type: GrantFiled: December 14, 2011Date of Patent: September 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Adam D. Miller
-
Patent number: 8518450Abstract: The invention provides a process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by preparing a double emulsion of water-oil-water including one or more polymer which forms the basis of the nanoparticle carrier, blending the drug to be delivered into one of the emulsion phases, doping either the oil-phase or the outer-water phase with a carbohydrate, and spray drying the emulsion to form nanoparticles of a narrow particle size distribution of 100 nm to 1000 nm, which nanoparticles are substantially spherical.Type: GrantFiled: August 17, 2010Date of Patent: August 27, 2013Assignee: CSIRInventor: Lonji Kalombo
-
Publication number: 20130216624Abstract: The present invention relates to sustained-release pellets containing tacrolimus as an active ingredient. The sustained-release pellets of the present invention have multiple layers of hydroxypropyl methylcellulose, and may control the release of drugs by specific contents of hydroxypropyl methylcellulose and Surelease™, thus rendering the dissolution rate thereof uniform and stable, and enabling the dissolution rate to be adjusted as desired. The entire process for preparing the pellets of the present invention is carried out in a single fluidized-bed granulator, and therefore the preparation process is simplified and the time required for preparation is shortened while obtaining sustained-release pellets having uniform particle size distribution and contents. The sustained-release pellets of the present invention may have medicinal effects that last up to 24 hours, and therefore may be administered just once a day, thus improving patient compliance.Type: ApplicationFiled: October 17, 2011Publication date: August 22, 2013Inventor: Hee-Yub Lee
-
Publication number: 20130209569Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.Type: ApplicationFiled: January 25, 2013Publication date: August 15, 2013Applicant: iCeutica, Inc.Inventor: iCeutica, Inc.
-
Publication number: 20130209540Abstract: The invention provides a multi-layered pharmaceutical composition comprising two or more formulations with varying properties. In some embodiments, the pharmaceutical compositions provide combinations of different organoleptic properties within the same product. In certain embodiment, these combinations allow for a modified release profile of active ingredients as the user enjoys the pharmaceutical composition. The invention further provides methods for making and using the pharmaceutical composition.Type: ApplicationFiled: February 10, 2012Publication date: August 15, 2013Inventors: Donna Walker Duggins, John-Paul Mua, Darrell Eugene Holton, JR., Daniel Verdin Cantrell
-
Patent number: 8507008Abstract: Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone defects are also disclosed.Type: GrantFiled: July 2, 2010Date of Patent: August 13, 2013Assignees: ETEX Corporation, Wyeth LLCInventors: Rebecca Li, Howard Seeherman, Hyun Kim
-
Patent number: 8506935Abstract: Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of ?-adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors, asthma antagonists, anti-endothelin drugs, prostacyclin drugs, ion channel or pump inhibitors, enhancers, or modulators and pharmaceutically acceptable analogs, derivatives, and mixtures thereof. Methods of treating a respiratory ailment using the described aerosols are also described. In general, the methods typically comprise the step of administering a therapeutically effective amount of respiratory drug condensation aerosol to a person with a respiratory ailment.Type: GrantFiled: June 23, 2009Date of Patent: August 13, 2013Assignee: Alexza Pharmaceuticals, Inc.Inventors: Ron L. Hale, Peter M. Lloyd, Amy T. Lu, Joshua D. Rabinowitz, Martin J. Wensley
-
Patent number: 8501240Abstract: The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject.Type: GrantFiled: December 23, 2008Date of Patent: August 6, 2013Assignee: Novartis AGInventors: Mei-chang Kuo, David Lechuga-Ballesteros
-
Patent number: 8501237Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.Type: GrantFiled: March 14, 2012Date of Patent: August 6, 2013Assignee: Tel-Aviv University Future Technology Development L.P.Inventors: Rimona Margalit, Noga Yerushalmi, Dan Peer, Ilia Rivkin
-
Patent number: 8496969Abstract: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses exceptionally good mouthfeel and stability.Type: GrantFiled: December 15, 2009Date of Patent: July 30, 2013Assignee: McNeil-PPC, Inc.Inventors: David Wynn, Nick Parikh
-
Patent number: 8496966Abstract: A quickly dissolving carrier granule made up of wood fibers, mineral filler, and starch-based or dextrin-based adhesive binder. The wood fibers in these granules are preferably wood fibers ranging from about 10 microns to about 2 mm in length. Typically, at least about 35 weight- % of the fibers are retained on a 50-Mesh U.S. Sieve Series screen. The wood fibers in this invention are derived from sources that are substantially free of resins such as urea-formaldehyde resin and of diphenylmethane diisocyanate resin. Typical binders are soluble dextrin binders or a viscous corn starch, wheat starch, rice starch, tapioca starch, potato starch, or sago starch binders. The granules have a Resistance to Attrition of at least 90%. Also disclosed is a method of making such granules.Type: GrantFiled: October 24, 2005Date of Patent: July 30, 2013Assignee: Cycle Group, Inc.Inventors: Yechiel Gilo, Steven G. Myers
-
Patent number: 8486438Abstract: The invention relates to the use of one or more growth factors in a drug delivery system, optionally with an external mesh housing, to recruit and optionally harvest progenitor cells. These cells include those that normally reside in the bone marrow.Type: GrantFiled: May 17, 2004Date of Patent: July 16, 2013Assignee: Brown UniversityInventors: Edith Mathiowitz, Diana M. James
-
Patent number: 8486043Abstract: Described here are unit dose containers, methods, and kits for treating asthma and other pulmonary conditions by nebulization. The unit doses of active agents are provided in a low volume formulation, which results in faster nebulization of the unit doses. The containers are also formed to minimize internal surface area so that effective re-dispersion of the active agents can be achieved while reducing adsorption to the walls of the containers.Type: GrantFiled: October 13, 2008Date of Patent: July 16, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Laxmi Iyer, Paul S. Uster
-
Patent number: 8470301Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.Type: GrantFiled: November 11, 2011Date of Patent: June 25, 2013Assignee: Nektar TherapeuticsInventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
-
Patent number: 8449917Abstract: The present invention concerns stable herbicidal solid compositions containing built-in adjuvant which exhibit improved herbicidal efficacy when used to control weeds in flooded rice paddies or fields.Type: GrantFiled: July 14, 2011Date of Patent: May 28, 2013Assignee: Dow AgroSciences, LLCInventors: Hiteshkumar Dave, Lei Liu, Raymond E. Boucher, Jr., David G. Ouse, Richard K. Mann, James M. Gifford, Yi-hsiou Huang, Åndrea C. McVeigh-Nelson, Martin C. Logan, Ashish Batra
-
Patent number: 8445026Abstract: Novel methods for biological effective, stable amorphous and monoclinic selenium nanoparticles are disclosed. They are prepared by reacting selenium source with a reducing agent or an oxidative agent in an aqueous media at a temperature between 0-100° C. in the presence of selenium binding polymer molecules such as poly/oligopeptide acids or peptone or nucleic acids or poly/oligosaccharide or their mixtures.Type: GrantFiled: November 21, 2008Date of Patent: May 21, 2013Inventors: Xueyun Gao, Yi Sun
-
DOSAGE FORM, AND METHODS OF MAKING AND USING THE SAME, TO PRODUCE IMMUNIZATION IN ANIMALS AND HUMANS
Publication number: 20130122106Abstract: An embodiment of the present invention features a dosage form for administering antigen to cause an immune response in an animal or human subject in the nature of a vaccine. The dosage form comprises spheres having an effective amount of antigen to create an immune response and having an average diameter of 0.01 to 10.0 microns. The spheres comprise a polymer selected from the group consisting of poly(L-lactic acid), poly(D, L-lactic acid), poly(glycolic acid) and carboxylic acid and ester derivatives thereof, poly(fumaric anhydride) and poly(sebacic anhydride) and derivatives thereof. The spheres can be lyophilized and stored as a powder prior to use. The spheres can then be reconstituted and formulated in buffers with adjuvants.Type: ApplicationFiled: October 19, 2012Publication date: May 16, 2013Applicant: Aphios CorporationInventor: Aphios Corporation -
Publication number: 20130122105Abstract: A composition and method comprising an anti-adjuvant such as DOI (an anti-inflammatory) together with any gene therapy plasmid is disclosed. A method for GHRH production in-vivo using a set of compositions and methods for use of those compositions is provided.Type: ApplicationFiled: November 16, 2011Publication date: May 16, 2013Inventor: Brian P. Hanley
-
Patent number: 8440731Abstract: Provided is a method for producing a functional material, including the steps of: bringing a polyvalent metal cation aqueous solution into contact with a base material; bringing a polyanion aqueous solution containing a functional component into contact with the base material previously in contact with the polyvalent metal cation aqueous solution to bond the polyvalent metal cations and the polyanions to each other, and thereby forming an insoluble compound containing the functional component; and drying the base material including the insoluble compound.Type: GrantFiled: January 22, 2008Date of Patent: May 14, 2013Assignee: Unicharm CorporationInventors: Hideaki Ichiura, Masaaki Morikawa, Masaki Takahashi, Noriyoshi Nishida, Takamitsu Igaue, Takayoshi Konishi
-
Publication number: 20130115302Abstract: A polysaccharide micro-particle encapsulating a growth factor is disclosed and shall include one or more growth factors, and a polysaccharide shell forming a space to encapsulate the growth factor by electrostatic interaction. Also, a method for manufacturing a polysaccharide micro-particle encapsulating a growth factor is disclosed, which shall include the following process: (A) providing a pH 4.6-6 polysaccharide solution and a growth factor; and (B) adding the growth factor to the polysaccharide solution, and adjusting the polysaccharide solution to a pH of 6-8 to obtain the polysaccharide micro-particle encapsulating the growth factor by electrostatic interaction. According to the polysaccharide shell structure, the growth factor can be stored for a long period of time and heal skin wounds, mucositis, and corneal ulcer effectively.Type: ApplicationFiled: April 4, 2012Publication date: May 9, 2013Applicant: MICORNA DERMAL THERAPY LAB CO., LTD.Inventor: Le Shin CHANG
-
Patent number: 8435554Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.Type: GrantFiled: December 30, 2008Date of Patent: May 7, 2013Assignee: Shin Nippon Biomedical Laboratories, Ltd.Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
-
Publication number: 20130108704Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.Type: ApplicationFiled: December 17, 2012Publication date: May 2, 2013Applicant: AICURIS GMBH & CO. KGInventor: AiCuris GmbH & Co. KG
-
Patent number: 8431161Abstract: A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly(hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the hydrophilic active substance, and a release of the hydrophilic active substance at an appropriate speed in the human body, and is hence very useful as a DDS pharmaceutical preparation.Type: GrantFiled: February 20, 2009Date of Patent: April 30, 2013Assignee: Toray Industries, Inc.Inventors: Yoshinori Kakizawa, Reiji Nishio, Junji Michizoe, Masakazu Koiwa, Nobuo Ida, Taisuke Hirano, Yoichiro Koshi
-
Patent number: 8431160Abstract: Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adjuvant and a combination thereof. Also described are methods of making such compositions and methods of administering such compositions. Methods of modulating the release rate of immunological species from microparticles are also described. These methods comprise varying the ratio of the cationic polysaccharide relative to the biodegradable polymer within the microparticles.Type: GrantFiled: February 24, 2007Date of Patent: April 30, 2013Assignee: Novartis AGInventors: Derek O'Hagan, Manmohan Singh, Janet Wendorf, Jina Kazzaz, Padma Malyala
-
Publication number: 20130101664Abstract: The present invention is directed to improved compositions for the disruption of signaling through the external domain (ED) of MUC1, Ligand traps—molecules that include MUC1 ED sequences and immunoglobulin Fc domains—effectively “trap” molecules that interact with the native MUC1 ED. Given the involvement of MUC1 in a variety of disease states, disrupting the interaction of other molecules with MUC1 ED is useful in treating these disease, in particular cancer.Type: ApplicationFiled: August 17, 2012Publication date: April 25, 2013Inventors: Donald W. Kufe, Surender Kharbanda
-
Patent number: 8420124Abstract: The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique.Type: GrantFiled: July 6, 2007Date of Patent: April 16, 2013Assignee: The University of North Carolina at Chapel HillInventors: Joseph M. DeSimone, Jason P. Rolland, Benjamin W. Maynor, Larkin E. Euliss, Ginger Denison Rothrock, Ansley E. Dennis, Edward T. Samulski, R. Jude Samulski
-
Patent number: 8409590Abstract: Anthrax antigens are provided that find use as immunogens and vaccines.Type: GrantFiled: February 11, 2005Date of Patent: April 2, 2013Assignee: Ligocyte Pharmaceuticals, Inc.Inventor: Susan Wimer-Mackin
-
Patent number: 8409617Abstract: A powder composition containing at least one fat-soluble vitamin dispersed in a matrix of a natural polysaccharide gum or a mixture of gums having an emulsifying capacity and/or a protein or a mixture of proteins having an emulsifying capacity. The fat-soluble vitamin in the powder compositions is in the form of droplets having an average diameter in the range of about 70 to about 200 nm. Tablets, beverages and beverage concentrates, foods, cosmetics and pharmaceuticals containing the powder composition can be made.Type: GrantFiled: November 30, 2000Date of Patent: April 2, 2013Assignee: DSM Nutritional Products Inc.Inventors: Chyi-Cheng Chen, Bruno Leuenberger